Hodge J W, Grosenbach D W, Rad A N, Giuliano M, Sabzevari H, Schlom J
Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Building 10, Room 8B07, 10 Center Drive, Bethesda, MD 20892-1750, USA.
Vaccine. 2001 May 14;19(25-26):3552-67. doi: 10.1016/s0264-410x(01)00062-7.
Recombinant orthopox vectors (both replication-defective fowlpox [rF], and replication competent vaccinia [rV] have been developed that simultaneously express three T-cell costimulatory molecule transgenes. The constituents of this triad of costimulatory molecules (designated TRICOM) are B7-1, ICAM-1, and LFA-3. We have previously shown that infection of murine dendritic cells (DCs) with TRICOM vectors increases their level of expression of the triad of costimulatory molecules and enhances the efficacy of DCs to activate T cells. While DCs are arguably the most potent antigen presenting cell (APC), limitations clearly exist in their use due to the level of effort and cost for their generation. The studies reported here demonstrate that a generic APC population, murine splenocytes, can be made markedly more efficient as APCs by infection with either rF-TRICOM or rV-TRICOM vectors. Infection of splenocytes with either TRICOM vector led to significant improvement of APC capabilities in terms of: (a) enhancement of mixed lymphocyte reactions; (b) a reduction in the amount of signal 1 to activate naive T cells; and (c) a reduction in the amount of APCs required to activate T cells using a constant amount of signal 1. TRICOM-enhanced T-cell activation was shown to correspond to increases in type-1 cytokines and a reduced level of apoptosis, compared with T cells activated with uninfected or control vector-infected splenocytes. In vitro and in vivo experiments compared DCs with TRICOM-infected splenocytes. Infection of splenocytes with TRICOM vectors markedly enhanced their ability to activate T cells to levels approaching that of DCs. These studies thus demonstrate for the first time that an abundant and accessible population of APCs obtainable without lengthy culture or the use of costly exogenous cytokines (in contrast to that of DCs) can be made more potent as APCs with the use of vectors that express a triad of costimulatory molecules.
已经开发出重组正痘病毒载体(包括复制缺陷型禽痘病毒[rF]和复制能力强的痘苗病毒[rV]),它们可同时表达三个T细胞共刺激分子转基因。这个共刺激分子三联体(命名为TRICOM)的组成成分是B7-1、ICAM-1和LFA-3。我们之前已经表明,用TRICOM载体感染小鼠树突状细胞(DCs)会增加它们共刺激分子三联体的表达水平,并增强DCs激活T细胞的功效。虽然DCs可以说是最有效的抗原呈递细胞(APC),但由于其产生所需的工作量和成本,在其使用中显然存在局限性。此处报道的研究表明,通过用rF-TRICOM或rV-TRICOM载体感染,普通的APC群体(小鼠脾细胞)可以作为APC变得明显更有效。用任何一种TRICOM载体感染脾细胞都会在以下方面显著提高APC的能力:(a)增强混合淋巴细胞反应;(b)减少激活初始T细胞所需的信号1量;(c)使用恒定信号1量激活T细胞所需的APC量减少。与用未感染或对照载体感染的脾细胞激活的T细胞相比,TRICOM增强的T细胞激活表现为1型细胞因子增加和凋亡水平降低。体外和体内实验比较了DCs和TRICOM感染的脾细胞。用TRICOM载体感染脾细胞显著增强了它们激活T细胞的能力,使其水平接近DCs。因此,这些研究首次证明,无需长时间培养或使用昂贵的外源性细胞因子(与DCs不同)即可获得的丰富且易于获取的APC群体,通过使用表达共刺激分子三联体的载体可作为更有效的APC。